📊 INTS Key Takeaways
Is INTS a Good Investment? Thesis Analysis
Intensity Therapeutics is a pre-revenue clinical-stage biopharmaceutical company with no sales generation, demonstrating severe cash burn of $9.2M annually. With only $11.9M in cash and negative operating income of $12M, the company has approximately 1.3 years of runway at current burn rates, creating existential liquidity risk. Negative returns on equity (-97.7%) and assets (-82.3%), combined with deteriorating financial position, indicate unsustainable operations without significant capital raises or clinical breakthroughs.
Why Buy INTS? Key Strengths
- Strong liquidity position with $11.9M cash equivalent to total stockholders equity
- Zero debt burden providing financial flexibility for restructuring or strategic alternatives
- Minimal liabilities ($2.2M) reducing near-term financial obligations
INTS Investment Risks to Consider
- No revenue generation with pre-clinical stage pharmaceutical operations creating unlimited burn scenario
- Severe cash burn rate of $9.2M annually implies only ~1.3 years of operational runway at current rates
- Pre-revenue stage with no indication of product commercialization timeline or clinical trial success rates
- Persistent negative profitability (-$12M operating loss) with no clear path to breakeven
- Dilution risk from future equity financing requirements to sustain operations
Key Metrics to Watch
- Cash burn rate and runway remaining until liquidity exhaustion
- Clinical trial progress and regulatory pathway advancement
- Capital raise timing, size, and dilution percentage
- Operating cash flow improvement trajectory toward breakeven
INTS Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.92x current ratio provides a solid financial cushion.
INTS Profitability Ratios
INTS vs Healthcare Sector
How INTENSITY THERAPEUTICS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is INTS Overvalued or Undervalued?
Based on fundamental analysis, INTENSITY THERAPEUTICS, INC. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
INTS Balance Sheet & Liquidity
INTS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: INTENSITY THERAPEUTICS, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-29.24 indicates the company is currently unprofitable.
INTS Growth Metrics (YoY)
INTS Capital Allocation
INTS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for INTENSITY THERAPEUTICS, INC. (CIK: 0001567264)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INTS
What is the AI rating for INTS?
INTENSITY THERAPEUTICS, INC. (INTS) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are INTS's key strengths?
Claude: Strong liquidity position with $11.9M cash equivalent to total stockholders equity. Zero debt burden providing financial flexibility for restructuring or strategic alternatives.
What are the risks of investing in INTS?
Claude: No revenue generation with pre-clinical stage pharmaceutical operations creating unlimited burn scenario. Severe cash burn rate of $9.2M annually implies only ~1.3 years of operational runway at current rates.
What is INTS's revenue and growth?
INTENSITY THERAPEUTICS, INC. reported revenue of N/A.
Does INTS pay dividends?
INTENSITY THERAPEUTICS, INC. does not currently pay dividends.
Where can I find INTS SEC filings?
Official SEC filings for INTENSITY THERAPEUTICS, INC. (CIK: 0001567264) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INTS's EPS?
INTENSITY THERAPEUTICS, INC. has a diluted EPS of $-8.56.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INTS a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, INTENSITY THERAPEUTICS, INC. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INTS stock overvalued or undervalued?
Valuation metrics for INTS: ROE of -97.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INTS stock in 2026?
Our dual AI analysis gives INTENSITY THERAPEUTICS, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INTS's free cash flow?
INTENSITY THERAPEUTICS, INC.'s operating cash flow is $-9.2M, with capital expenditures of N/A.
How does INTS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -97.7% (avg: 15%), current ratio 5.92 (avg: 2).